Current concepts on antibiotic resistance and therapeutic problems raised by pseudomonas aeruginosa;Resistance aux antibiotiques et problemes therapeutiques poses par pseudomonas aeruginosa

Presse Medicale

Volumn 28, Issue 8, 1999, Pages 451-458

  Bert, F ^a   Lambert Zechovsky, N ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BACTERIAL ENZYME; CEFTAZIDIME; CEPHALOSPORIN; CEPHALOSPORINASE; ISEPAMICIN; PENICILLINASE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TAZOBACTAM; TICARCILLIN; BETA LACTAMASE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ENZYME ACTIVITY; INCIDENCE; MEMBRANE PERMEABILITY; PENICILLIN RESISTANCE; PSEUDOMONAS AERUGINOSA; REVIEW; CROSS INFECTION; DRUG EFFECT; GRAM NEGATIVE INFECTION; HUMAN; IMMUNOLOGY; MICROBIOLOGY;

BETA-LACTAMASES; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; HUMANS; PENICILLINASE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 0033608303     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Spencer RC. Predominant pathogens found in the European prevalence of infection in intensive care study. Eur J Clin Microbiol Infect Dis 1996 ; 15:281-5.
2. Nakae T. Role of membrane permeability in determining antibiotic resistance in Pseudomonas aeruginosa. Microbiol Immunol 1995 ; 39:221-9.
3. Li X-Z, Ma D, Livermore DM, Nikaido H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to β-lactam resistance. Antimicrob Agents Chemother 1994 ; 18:1742-52.
4. Li X-Z, Nikaido H, Poole K. Role of MexA-MexB-OprM in antibiotic efflux in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995 ; 39:1948-53.
5. Livermore DM. β-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995 ; 8:557-84.
6. Thabaut A, Philippon A, Meyran M. β-lactamases of Pseudomonas aeruginosa and susceptibility against β-lactam antibiotics. Chemioterapia 1985 ; 4:36-42.
7. Chen HY, Yuan M, Livermore DM. Mechanisms of resistance to β-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993. J Med Microbiol 1995 ; 43:300-9.
8. Bert F, Briaud I, Branger C, Lambert-Zechovsky N. Comparaison de l'activité des β-lactamines sur Pseudomonas aeruginosa en fonction des phénotypes de résistance. Path Biol 1996 ; 44:329-32.
9. Thabaut A, Meyran M. Activité in vitro de l'association pipéracilline-tazobactam sur 224 souches de Pseudomonas aeruginosa en fonction de la production de bêtalactamase. Path Biol 1991 ; 39:361-6.
10. Jones RN, Marshall SA. Antimicrobial activity of cefepime tested against Bush group I beta-lactamase-producing strains resistant to ceftazidime. A multilaboratory national and international clinical isolate study. Diagn Microbiol Infect Dis 1994 ; 19:33-8.
11. Nordmann P, Ronco E, Naas T, Duport C, Michel-Briand Y, Labia R. Characterization of a novel extended β-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1993 ; 37:962-9.
12. Philippon A. Pseudomonas aeruginosa: phénotypes de résistance aux antibiotiques. Méd Mal Infect 1998 ; 28 Spécial:134-49.
13. Watanabe M, Iyobe S, Inoue M, Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991 ; 35:147-51.
14. Senda K, Arakawa Y, Nakashima K et al. Multifocal outbreaks of metallo-β-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum β-lactams, including carbapenems. Antimicrob Agents Chemother 1996 ; 40:349-53.
15. Plesiat P, Ramos-Aires J, Pechere J-C, Kohler T. Systèmes d'efflux actifs chez Pseudomonas aeruginosa. Med Mal Infect 1998;28 Spécial:126-33.
16. Masuda N, Sakagawa E, Ohya S. Outer membrane proteins responsible for multiple drug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995 ; 39:645-9.
17. Bert F, Bruneau B, Lambert-Zechovsky N, Branger C. Comparative activity of β-lactam antibiotics against 'intrinsically' ticarcillin-resistant strains of Pseudomonas aeruginosa Chemother 1994 ; 40:183-7.
18. Leying HJ, Büscher KH, Cullmann W, Then RL. Lipopolysaccharide alterations responsible for combined quinolone and β-lactem resistance in Pseudomonas aeruginosa Chemother 1992 ; 38:82-91.
19. Liao X, Hancock REW Susceptibility to β-lactam antibiotics of Pseudomonas aeruginosa overproducing penicillin-binding protein 3. Antimicrob Agents Chemother 1997 ; 41:1158-61.
20. Büscher K-H, Cullmann W, Dick W, Opterkuch W. Imipenem resistance in Pseudomonas aeruginosa resulting from diminished expression of an outer membrane protein. Antimicrob Agents Chemother 1987 ; 31:703-8.
21. Livernore DM. Interplay of impermeability and chromosomal β-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992 ; 36:2046-8.
22. Pérez FI, Gimeno C, Navaro D, Garcia-de-Lomas J. Meropenem permeation through the outer membrane of Pseudomonas aeruginosa can involve pathways other than the OprD porin channel. Chemother 1996 ; 42:210-14.
23. Groupe d'étude de la résistance de Pseudomonas aeruginosa aux β-lactamines (GERPB). Surveillance de la résistance de Pseudomonas aeruginosa aux antibiotiques en milieu hospitalier. Lettre infectiol 1995 ; X:660-1.
24. Bert F, Lambert-Zechovsky N. Antibiotic resistance patterns in Pseudomonas aeruginosa: an 8-year surveillance study in a French hospital. Int J Antimicrob Agents 1997 ; 9:107-12.
25. Groupe d'étude de la résistance de Pseudomonas aeruginosa aux β-lactamines (GERPB). Mécanismes de la résistance aux bêtalactamines parmi les souches de Pseudomonas aeruginosa isolés en France (1994-1995-1996). Lettre Infectiol 1998 ; XIII: 106-7.
26. Vahaboglu H1 C̈ztürk, Aygün G et al. Widespread detection of PER-1 -type extended-spectrum β-lactamases among nosocomial Acinetobacter and Pseudomonas ceruginosa isolates in Turkey: a netionwide multicenter study. Antimicrob Agents Chemother 1997 ; 41:2265-9.
27. Chen HY, Yuan M, Ibrahim-Elmagboul IB, Livermore DM. National survey of susceptibility to antimicrobials amongst clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother 1995 ; 35:521-34.
28. Bert F, Maubec E, Bruneau B, Berry P, Lambert-Zechovsky N. Multi-resistant Pseudomonas aeruginosa outbreak associated with contaminated tap water in a neurosurgery intensive care unit. J Hosp Infect 1998 ; 39:53-62.
29. Pitt TL, Livermore DM, Miller G, Vatapoulos A, Legekis NJ. Resistance mechanisms of multiresistant serotype 012 Pseudomonas aeruginosa isolated in Europe. J Antimicrob Chemother 1990 ; 26:319-28.
30. Hachler H, Santanam P, Kayser FH. Sequence and characterization of 3 novel chromosomal aminoglycoside phosphotransferase gene, aph (3′)-llb, in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996 ; 40:1254-6.
31. The Aminoglycoside Resistance Study Groups. The most frequently occurring aminoglycoside resistance mechanisms-combined results of surveys in eight regions of the world. J Chemother 1995 ; 7 suppl. 2:17-30.
32. Karlowsky JA, Saunders MH, Harding GA, Hoban DJ, Zhanel GG In vitro characterization of aminoglycoside adaptative resistance in Pseudomoras aeruginosa. Antimicrob Agents Chemother 1996 ; 40:1387-93.
33. Xiong Y-Q, Caillon J, Kergueris MF et al. Adaptative resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model. Antimicrob Agents Chemother 1997 ; 41:823-6.
34. Cambau E. Résistance bactérienne aux quinolones. Méd Thér 1997 ; 1 suppl:98-107.
35. Masuda N, Ohya S. Cross-resistance to meropenem, cephems, and quinolones in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992 ; 36:1847-51.
36. Masuda N, Gotoh N, Ohya S, Nishino T. Quantitative correlation between susceptibility and OprJ production in NfxB mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996 ; 40:909-13.
37. Aubert G, Pozzetto B, Dorche G. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy. J Antimicrob Chemother 1992 ; 29:307-12.
38. Yoshida T, Muratani T, Iyobe S, Mitsuhashi S. Mechanisms of high-level resistance to quinolones in urinary tract isolates of Pseudomonas aeruginoso. Antimicrob Agents Chemother 1994 ; 18:1466-9.
39. Carrbau E, Perani E, Dib C, Petinon C, Trias J, Jarlier V. Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem. Antimicrob Agents Chemother 1995 ; 19:2248-52.
40. Gibert C. Traitement des infections aiguës sévères à Pseudomonas aeruginosa chez l'adulte. Lettre Infectiol 1996 ; XI:136-43.
41. Fink MP, Snydman DR, Niederman MS et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother 1994 ; 38:547-57.
42. Cometta A, Baumgartner JD, Lew et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother 1994 ; 38:1309-13.
43. Vidal F, Mensa J, Almela M et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment Arch Intern Med 1996 ; 156:2121-6.
44. Gerçeker AA, Gürler B. In vitro activities of various antibiotics, alone and in combination with amikacin against Pseudomonas aeruginosa. J Antimicrob Chemother 1995 ; 36:707-11.
45. Canis F, Cavallo JD, Husson MO. Evaluation de l'activité bactéricide de l'association cefpirome-aminogtycosides sur des souches de Pseudomonas aeruginosa de sensibilité intermédiaire au cefpirome et appartenant à différents phénotypes de résistance aux bêta-lactamines. Pathol Boil 1997 ; 45:420-3.
46. Ciamarellos-Bourboulis EJ, Grecka P, Giamarellou H. Comparative in vitro interactions of ceftazidime, meropenem, and imipenem with amikacin on multiresistant Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 1997 ; 29:81-6.
47. Tessier F, Quentin C. In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 1997 ; 16:159-62.
48. Xiong Y-Q, Potel G, Caillon J et al. Comparative efficacies of ciprofloxacin and pefloxacin alone or in combination with fosfomycin in experimental endocarditis induced by multidrug-susceptible and resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995 ; 39:496-9.
49. Xiong Y-Q, Caillon J, Drugeon H, Potei G, Baron D. The effect of rifampicin on adaptative resistance of Pseudomonas aeruginosa to aminoglycosides. J Antimicrob Chemother 1996 ; 37:993-8.
50. Korvick JA, Peacock JE, Muder RR, Wheeler RR, Yu VL. Addition of rifampicin to combination antibiotic therapy for Pseudomonas aeruginosa bacteremia: prospective trial using the zelen protocol. Antimicrob Agents Chemother 1992 ; 36:620-5.
51. Mouton JW, Den Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994 ; 38:931-6.
52. Maggiolo F, Taras A, Frontespezi S et al. Pharmacodynamic effects of subinhibitory concentrations of imipenem on Pseudomonas aeruginosa in an in vitro dynamic model. Antimicrob Agents Chemother 1994 ; 38:1416-18.
53. Karlowsky JA, Zhanel GG, Davidson RJ, Hoban DJ. Oncedaily ammoglycoside dosing assessed by MIC reversion time with Pseudomonas aeruginosa. Antimicrob Agents Chemother 1994 ; 38:1165-8.
54. Xiong Y-Q, Caillon J, Kergueris MF et al Adaptative resistance of Pseudomonos ceroginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model. Antimicrob Agents Chemother 1997 ; 41:823-6.
55. Barclay ML, Begg FJ, Chambers ST, Boswell DR. Improved efficacy with nonsimultaneous administration of first doses of gentamicin anf ceftaadime in vitro. Antimicrob Agents Chemother 1995 ; 39:132-6.
56. Forrest A, Nick DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993 ; 17:1073-81.
57. Troillet N, Samore MH, Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis 1997 ; 25:1094-8.
58. Brown RB, Kruse JA, Counts CW, Russell JA, Chnstou NV, Sands ML. Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. Antimicrob Agents Chemother 1990 ; 34:269-72.
59. Watanabe NA. Newer antipseudomonal cephalosporins J Chemother 1995 ; 8(suppl 2):48-56.
60. Livermore DM, Chen HY. Potentiation of β-lactams against Pseudomonas aerugirosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC β-lactamases. J Antimicrob Chemother 1997 ; 40:335-43.
61. Omri A, Ravaoarinoro M, Poisson M. Incorporation, release and in-vitro antibacterial activity of liposomal aminoglycosides against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995 ; 36:631-9.